[Form 4] OPKO HEALTH, INC. Insider Trading Activity

Rhea-AI Filing Summary

OPKO Health (OPK) insider trading report: Phillip Frost, M.D., who serves as CEO, Chairman, director and a 10% owner of OPKO Health, reported a series of open-market purchases of the company’s common stock. On 11/20/2025, he bought a total of 580,000 common shares in multiple trades at prices ranging from $1.32 to $1.35 per share, all reported as indirect ownership through Frost Gamma Investments Trust. After these transactions, one reported indirect position shows 216,126,448 shares beneficially owned. The filing also lists 3,568,951 shares held directly and an additional 30,127,177 shares held indirectly through Frost Nevada Investments Trust. The report states that beneficial ownership is disclaimed except to the extent of any pecuniary interest.

Insights

Equity Analyst

CEO/Chairman and 10% owner increased indirect stake via open-market purchases on 11/20/2025, a conventionally favorable insider-activity signal.

The filing shows multiple open-market purchases of **Common Stock** on 11/20/2025 at prices between $1.32 and $1.35. The total of these trades is 580,000 shares, increasing one indirect holding to **216,126,448** shares. The transaction code **"P"** indicates standard purchases rather than option exercises or grants.

These shares are held through a layered trust and partnership structure (Frost Gamma Investments Trust and related entities), and the reporting person expressly disclaims beneficial ownership beyond any economic interest. Another block of **3,568,951** shares is listed as directly owned, and **30,127,177** shares as indirectly owned through a separate Frost Nevada structure, also with a similar ownership disclaimer. The person remains a **Director**, **CEO & Chairman**, and **10% Owner**, so this activity relates to an already large, influential stake.

Insider open-market purchases by a senior control figure often align with a constructive view of their economic exposure, though no motive is stated. The key concrete items to monitor from this disclosure are the increased indirect position to **216,126,448** shares as of 11/20/2025 and the continued use of trust and partnership vehicles, which shape how control and economic interests are organized over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		P		119,129	A	$1.32	215,665,577	I	See Footnote(1)
Common Stock	11/20/2025		P		47,105	A	$1.325	215,712,682	I	See Footnote(1)
Common Stock	11/20/2025		P		211,948	A	$1.33	215,924,630	I	See Footnote(1)
Common Stock	11/20/2025		P		161,818	A	$1.335	216,086,448	I	See Footnote(1)
Common Stock	11/20/2025		P		24,579	A	$1.34	216,111,027	I	See Footnote(1)
Common Stock	11/20/2025		P		1,757	A	$1.345	216,112,784	I	See Footnote(1)
Common Stock	11/20/2025		P		13,664	A	$1.35	216,126,448	I	See Footnote(1)
Common Stock								3,568,951	D
Common Stock								30,127,177	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

1. Name and Address of Reporting Person^*

Frost Gamma Investments Trust

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

2. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

	Phillip Frost, M.D., Individually and as Trustee	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OPKO Health (OPK) report on this Form 4?

The filing reports that Phillip Frost, M.D., a director, CEO, Chairman and 10% owner of OPKO Health, made multiple open-market purchases of the company’s common stock on 11/20/2025.

How many OPKO Health (OPK) shares did Phillip Frost purchase and at what prices?

Phillip Frost purchased a total of 580,000 OPKO Health common shares on 11/20/2025 in several trades at prices between $1.32 and $1.35 per share.

What is Phillip Frost’s reported beneficial ownership in OPKO Health after the transactions?

Following the reported trades, one indirect position through Frost Gamma Investments Trust shows 216,126,448 shares beneficially owned. The filing also lists 3,568,951 shares held directly and 30,127,177 shares held indirectly through Frost Nevada Investments Trust.

How are the newly purchased OPKO Health shares held?

The acquired OPKO Health common stock is reported as indirectly owned through Frost Gamma Investments Trust, with the nature of indirect beneficial ownership described in the footnotes.

What do the footnotes say about Phillip Frost’s beneficial ownership of OPKO Health shares?

The footnotes explain that the securities are held through entities including Frost Gamma Investments Trust and Frost Nevada Investments Trust, and state that the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

What is Phillip Frost’s relationship to OPKO Health (OPK)?

Phillip Frost is identified as a Director, CEO & Chairman, and a 10% Owner of OPKO Health.